Stock · TMO · Healthcare
United States · Large Cap · listed since 1978 · Revenue 12 mo. $47.4B
Price as of 11/06/2026
Summary
46.9 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €5.6B (2025), it supports €62.7B. The remaining €173.1B of the market value assume it grows 18.4% a year for 10 years and not at all afterwards.
Required FCF growth per year
18.4%
no growth afterwards
Price to operating cash flow 27.6×, above its usual range.
Middle half of 20 quarters: 23.1× to 26.2×, median 24.0×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
AI summary of the 2025 annual report
A language model selected and condensed statements from the report. Each statement carries a verbatim quote. The selection is not complete and shows the state of the report. It gives no rating and does not feed into the score.
Form 10-K, fiscal year ended 12/31/2025, filed 02/26/2026. Open the report at the SEC
| Segment | Share | Revenue |
|---|---|---|
| Laboratory Products and Biopharma Services | 51.5% | $24B |
| Life Sciences Solutions | 22.3% | $10.4B |
| Analytical Instruments | 16.2% | $7.6B |
| Specialty Diagnostics | 10.0% | $4.7B |
From the report's structured data (XBRL), not from the language model. The sum can differ slightly from group revenue.
Internal revenue between segments: −$2B
The Life Sciences Solutions segment provides reagents, instruments and consumables for biological and medical research, drug and vaccine discovery and production, and disease diagnosis.
Through our Life Sciences Solutions segment, we provide an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease.The Analytical Instruments segment provides instruments, plus the consumables, software and services that go with them, for a range of applications.
Through our Analytical Instruments segment, we provide a broad offering of instruments and the supporting consumables, software and services that are used for a range of applications.The Specialty Diagnostics segment offers diagnostic test kits, reagents, culture media, instruments and related products for healthcare, clinical, pharmaceutical, industrial and food safety laboratories.
Our Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories.The laboratory products offering includes lab consumables, equipment and chemicals used in life science research and drug discovery and development.
Our laboratory products include lab consumables, equipment and chemicals that are used for life science research and drug discovery and development.The pharma services business offers development, manufacturing and clinical trial services for small-molecule and large-molecule pharmaceuticals.
Our pharma services business provides the entire spectrum of development, manufacturing and clinical trials services for both small-molecule and large-molecule pharmaceuticals.Customers include pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies.
We serve customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies.The healthcare market channel offers products and services for hospitals, clinical laboratories, reference laboratories, physicians’ offices and other clinical testing facilities.
Our healthcare market channel offerings include a broad array of consumables, diagnostic kits and reagents, equipment, instruments, solutions and services for hospitals, clinical laboratories, reference laboratories, physicians’ offices and other clinical testing facilities.The company faces aggressive and able competition in virtually all of the markets it serves.
The company encounters aggressive and able competition in virtually all of the markets we serve.Competition depends on factors including technological innovation and adoption of AI, price, service and delivery, breadth of product line, customer support and e-business capabilities.
Competitive factors include technological innovation, including the timely, responsible and effective adoption of emerging technologies (such as AI), price, service and delivery, breadth of product line, customer support, e-business capabilities and the ability to meet the special requirements of customers.Competitors include a broad range of manufacturers, third-party distributors and service providers.
Our competitors include a broad range of manufacturers, third-party distributors and service providers.Relying on sole or limited suppliers for certain materials or components could cause production interruptions, delays and inefficiencies.
Our reliance upon sole or limited sources of supply for certain materials or components could cause production interruptions, delays and inefficiencies.If the company cannot realize the value of its goodwill and intangible assets, it may have to record material impairment charges on those assets.
If we are not able to realize the value of the goodwill and intangible assets, we may be required to incur material charges relating to the impairment of those assets.Pharma services are very complex. If the company is unable to provide quality and timely offerings to customers, its business could suffer.
Our pharma services offerings are highly complex, and if we are unable to provide quality and timely offerings to our customers, our business could suffer.Intellectual property rights may be unavailable or limited in some foreign countries, which could make it easier for competitors to gain market position.
Intellectual property rights may also be unavailable or limited in some foreign countries, which could make it easier for competitors to capture increased market position.Since the last quarter
Q2 → Q3 2026
8 more unchanged: Revenue, 12 mo., FCF, 12 mo., Gross margin, EBIT margin, FCF margin, Net debt, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 12.61% | 11.52% | Rank 58 |
| Return on capital (Greenblatt) | 33.67% | 32.55% | Rank 53 |
| EBIT margin | 18.20% | 18.31% | Rank 50 |
| FCF margin | 14.12% | 14.12% | Rank 50 |
| Gross margin | 40.93% | 60.99% | Rank 25 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 3.91% | 8.04% | Rank 24 |
| Earnings growth, 3 years per year | 0.43% | 5.44% | Rank 36 |
| Earnings growth, 5 years per year | 2.26% | 7.00% | Rank 34 |
| Sustainable growth (ROE × retained earnings) | 3.42% | 3.66% | Rank 42 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 2.57% | 2.90% | Rank 40 |
| FCF yield | 2.39% | 3.63% | Rank 28 |
| EV/saleslower is better | 6.56 | 4.03 | Rank 31 |
| EV/EBITlower is better | 36.02 | 21.73 | Rank 17 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 13.15% | 8.66% | Rank 55 |
| Share price, 6 months | 49.89% | 24.27% | Rank 86 |
| Share price, 3 months | 22.09% | 15.42% | Rank 72 |
| Distance from 52-week high | −2.03% | −7.35% | Rank 75 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 2.86% | 0.30% | Rank 29 |
| Change in share countlower is better | −1.57% | 0.00% | Rank 73 |
| Dividend streak in years | 13 | 10 | Rank 69 |
| Price reaction to results, market-adjusted | 0.44% | 0.05% | Rank 55 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 48.40% | 48.40% | Rank 50 |
| Net debt/EBITDAlower is better | 2.55 | 1.11 | Rank 23 |
| Debt to equitylower is better | 0.74 | 0.48 | Rank 34 |
| Volatility, 1 yearlower is better | 29.33% | 31.42% | Rank 66 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $B | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 18.3 | 15.6% | 2.7 | 397M | 15.8 |
| 2017 | 20.9 | 15.6% | 3.5 | 398M | 19.6 |
| 2018 | 24.4 | 15.9% | 3.8 | 406M | 16.9 |
| 2019 | 25.5 | 16.7% | 4.0 | 403M | 16.1 |
| 2020 | 32.2 | 24.5% | 6.8 | 399M | 12.2 |
| 2021 | 39.2 | 26.3% | 7.0 | 397M | 31.9 |
| 2022 | 44.9 | 19.0% | 6.9 | 394M | 27.5 |
| 2023 | 42.9 | 16.0% | 6.9 | 388M | 28.3 |
| 2024 | 42.9 | 17.9% | 7.3 | 383M | 28.8 |
| 2025 | 44.6 | 18.2% | 6.3 | 377M | 29.5 |
3 of 7 StockScorer Score rules met · How the score is built
Thermo Fisher Scientific Inc mainly meets criteria in the Profitability category. Result from 18 strategies checked.
Thermo Fisher Scientific Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
5 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Thermo Fisher Scientific Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 38.9 | 30.0 |
| P/B ratio | 4.9 | 4.8 |
| Return on equity (ROE) | 12.6% | 11.5% |
| Equity ratio | 48.4% | 48.4% |
| Debt-to-equity (D/E) | 0.74 | 0.48 |
| Dividend yield | 0.3% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| TMO | Thermo Fisher Scientific Incthis page | |
| DHR | Danaher Corporation | Low3.6 |
| 2359.HK | WuXi AppTec Co Ltd H | locked |
| LONN.SW | Lonza Group AG | locked |
| A | Agilent Technologies Inc | locked |
| NTRA | Natera Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.